Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

ClinicalTrials.gov ID: NCT03052725

Public ClinicalTrials.gov record NCT03052725. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Study identification

NCT ID
NCT03052725
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
391 participants

Conditions and interventions

Interventions

  • reslizumab Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 9, 2017
Primary completion
Feb 21, 2018
Completion
Feb 21, 2018
Last update posted
Dec 13, 2022

2017 – 2018

United States locations

U.S. sites
37
U.S. states
20
U.S. cities
34
Facility City State ZIP Site status
Teva Investigational Site 14647 Birmingham Alabama 35209
Teva Investigational Site 14631 Bakersfield California 93301
Teva Investigational Site 14648 Huntington Beach California 92647
Teva Investigational Site 14637 Napa California 94558
Teva Investigational Site 14654 Stockton California 95207
Teva Investigational Site 14636 Walnut Creek California 94598
Teva Investigational Site 14626 Aventura Florida 33180
Teva Investigational Site 14634 Homestead Florida 33030
Teva Investigational Site 14650 Miami Florida 33015
Teva Investigational Site 14629 Miami Florida 33173
Teva Investigational Site 14619 Miami Florida 33186
Teva Investigational Site 14624 Orlando Florida 32819
Teva Investigational Site 14638 Tallahassee Florida 32308
Teva Investigational Site 14642 Buford Georgia 30518
Teva Investigational Site 14651 Chicago Illinois 60612
Teva Investigational Site 14645 Michigan City Indiana 46360
Teva Investigational Site 14620 Owensboro Kentucky 42301
Teva Investigational Site 14623 Lafayette Louisiana 70508
Teva Investigational Site 14627 North Dartmouth Massachusetts 02747
Teva Investigational Site 14644 Boys Town Nebraska 68010
Teva Investigational Site 14652 Ocean City New Jersey 07712
Teva Investigational Site 14632 Lake Success New York 11042
Teva Investigational Site 14646 New York New York 10016-9196
Teva Investigational Site 14633 Cincinnati Ohio 45221
Teva Investigational Site 14653 Cleveland Ohio 44106
Teva Investigational Site 14621 Edmond Oklahoma 73034
Teva Investigational Site 14625 Edmond Oklahoma 73034
Teva Investigational Site 14643 Jenkintown Pennsylvania 19046
Teva Investigational Site 14622 Pittsburgh Pennsylvania 15241
Teva Investigational Site 14630 East Providence Rhode Island 02914
Teva Investigational Site 14649 Providence Rhode Island 02909
Teva Investigational Site 14655 Knoxville Tennessee 37919
Teva Investigational Site 14639 Corsicana Texas 75110
Teva Investigational Site 14640 Dallas Texas 75225
Teva Investigational Site 14641 Provo Utah 84604
Teva Investigational Site 14628 Abingdon Virginia 24210
Teva Investigational Site 14635 Falls Church Virginia 22044

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03052725, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 13, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03052725 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →